Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 1/20 | 0.49 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.43 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691695 | 1.00 | CCNC (0.49) | CCNCCDK8PARP1DYRK1BNR4A2 | |
| SCHEMBL24478623 | 0.85 | MAP4K4 (0.53) | DYRK1BNR4A2PIK3CASLC22A12ALDH1A1 | |
| SCHEMBL856135 | 0.84 | FERMT2 (0.49) | CCNCCDK8NR4A2GAKAXL | |
| SCHEMBL30051309 | 0.79 | NR4A2 (0.66) | CCNCCDK8PARP1DYRK1BNR4A2 | |
| SCHEMBL1888577 | 0.79 | NR4A2 (0.66) | CCNCCDK8PARP1DYRK1BNR4A2 | |
| SCHEMBL4655567 | 0.78 | AXL (0.42) | CDK8DYRK1BNR4A2PIK3CAAXL | |
| SCHEMBL16248013 | 0.76 | CDK8 (0.49) | CCNCCDK8PARP1DYRK1BNR4A2 | |
| SCHEMBL359558 | 0.76 | NT5E (0.50) | CCNCCDK8DYRK1BNR4A2GAK | |
| SCHEMBL4758609 | 0.76 | LMNA (0.56) | PARP1DYRK1BNR4A2SLC22A12AXL | |
| SCHEMBL16705385 | 0.76 | CDK8 (0.49) | CCNCCDK8PARP1DYRK1BNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 338 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106565602-B | Preparation method of 4-chloro-6-fluoroquinoline | 常州市阳光药业有限公司 | 2020-09-08 | — | — | CN | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| CN-117120423-B | Indolylamine 2, 3-dioxygenase inhibitors, methods of preparing the same, and pharmaceutical compositions containing the same | 柳韩洋行 | 2026-02-27 | — | — | CN | disclosed |
| US-12551478-B2 | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) | 2026-02-17 | — | — | US | disclosed |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119462501-A | Preparation method of 2-quinolinamide compound promoted by acidic ionic liquid | 内蒙古民族大学 | 2025-02-18 | — | — | CN | disclosed |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-12065437-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-20 | — | — | US | disclosed |
| US-6339093-B1 | Isoquinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-01-15 | — | — | US | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| EP-1090917-A1 | Quinolin-4-yl derivatives and their use as NMDA-receptor subtype blockers | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-11 | — | — | EP | disclosed |
| EP-1088818-A1 | Quinolin-4-yl derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-04 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| EP-0168812-A1 | 4-Amino-2-phenyl quinolines, methods and intermediates for their preparation and medicaments containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1986-01-22 | — | — | EP | disclosed |
| US-4560692-A | ANTICONVULSANTS OR ANXIOLYTIC AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1985-12-24 | — | — | US | disclosed |
| US-4051247-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1977-09-27 | — | — | US | disclosed |
| US-3985753-A | ANTIBACTERIAL AGENTS | RIKER LABORATORIES, INC. (US) | 1976-10-12 | — | — | US | disclosed |
| US-3976651-A | BACTERICIDE | RIKER LABORATORIES, INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | CCNC 1900/4885CDK8 841/4885PARP1 3061/4885 |
| US-12551478-B2 | Quinoline derivative having indoleamine-2,3-dioxygenase inhibitory activity | IDO2, IDO1, HDAC2 | CCNC 2995/4885CDK8 1117/4885PARP1 695/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | CCNC 1992/4885CDK8 1953/4885PARP1 3877/4885 |
| US-12065437-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | CCNC 2463/4885CDK8 492/4885PARP1 1743/4885 |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | CCNC 1923/4885CDK8 419/4885PARP1 2888/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | CCNC 4661/4885CDK8 141/4885PARP1 866/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | CCNC 2463/4885CDK8 492/4885PARP1 1743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.